Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 14/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.35 |
| ▸ | OXTR | P30559 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31093304 | 0.91 | SCN9A (0.45) | SCN9ASLC22A12 | |
| SCHEMBL319158 | 0.91 | SCN9A (0.45) | SCN9ASLC22A12 | |
| SCHEMBL19627592 | 0.87 | SCN9A (0.43) | SCN9A | |
| SCHEMBL18352242 | 0.86 | SLC22A12 (0.39) | SCN9ASLC22A12SCN5A | |
| SCHEMBL16185267 | 0.85 | SLC22A12 (0.41) | SCN9ASLC22A12AVPR2OXTRAVPR1A | |
| SCHEMBL9923651 | 0.84 | SCN9A (0.44) | SCN9ASLC22A12 | |
| SCHEMBL16020177 | 0.84 | SCN9A (0.43) | SCN9A | |
| SCHEMBL16185266 | 0.83 | SLC22A12 (0.46) | SLC22A12 | |
| SCHEMBL16185279 | 0.83 | SLC22A12 (0.41) | SCN9ASLC22A12AVPR2OXTRAVPR1A | |
| SCHEMBL16185262 | 0.83 | SLC22A12 (0.39) | SCN9ASLC22A12SCN5AAVPR2OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586968-B2 | Bicycloamine-substituted-N-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170002008-A1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2017-01-05 | — | — | US | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002008-A1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | SCN1B, CACNA1E, CACNA1B | SCN9A 9/4885SLC22A12 2053/4885SCN5A 34/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885SLC22A12 999/4885SCN5A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.